Does the cyclosporine still have a potential role in the treatment of acute severe steroid-refractory ulcerative colitis?

Gut and Liver

Volumn 9, Issue 5, 2015, Pages 567-568

  Eun, Chang Soo ^a   Han, Dong Soo ^a  

^a Hanyang University Guri Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; IMMUNOSUPPRESSIVE AGENT;

DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; FEMALE; MALE; PROCEDURES; SALVAGE THERAPY;

COLITIS, ULCERATIVE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MALE; SALVAGE THERAPY;

EID: 84942084554     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl15293     Document Type: Editorial

References (9)

1. Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver 2015;9:18-27.
2. Seo HI, Park DI, Kim TO, et al. The effect of infliximab on patients with ulcerative colitis in Korea. Intest Res 2014;12:214-220.
3. Sjöberg M, Walch A, Meshkat M, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis 2012;18:212-218.
4. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013;38:294-302.
5. Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28:287-293.
6. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-1915.
7. Han DS. Current status and prospects of intestinal microbiome studies. Intest Res 2014;12:178-183.
8. Jung YS, Song CS, Kim ER, et al. Seasonal variation in months of birth and symptom flares in Korean patients with inflammatory bowel disease. Gut Liver 2013;7:661-667.
9. Kim EH, Kim DH, Park SJ, et al. Infliximab versus cyclosporine treatment for severe corticosteroid-refractory ulcerative colitis: a Korean, retrospective, single center study. Gut Liver 2015;9:601-606.